Literature DB >> 23634358

Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study.

Carlo Tornatore1, J Theodore Phillips, Omar Khan, Aaron E Miller, Christopher J Barnes.   

Abstract

We assess current practice patterns of US neurologists in patients with clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and radiologically isolated syndrome (RIS) using case-based surveys. For CIS, 87% recommended initiation of disease-modifying therapy (DMT) with MRI brain lesions. An injectable DMT was recommended by 90%-98% for treatment-naive, mild RRMS patients. There was 97% consensus to treat highly active RRMS, but no consensus on therapy choice. With RIS, there was consensus not to initiate treatment with brain but no spinal MRI lesions. Current US treatment patterns emphasize MRI in MS diagnosis and subsequent treatment decisions, treatment of early disease, aggressive initial treatment of highly active MS, and close patient monitoring.

Entities:  

Year:  2012        PMID: 23634358      PMCID: PMC3613193          DOI: 10.1212/CPJ.0b013e31824cb09b

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  18 in total

Review 1.  Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.

Authors:  A Clegg; J Bryant
Journal:  Expert Opin Pharmacother       Date:  2001-04       Impact factor: 3.889

Review 2.  MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

Authors:  Frederik Barkhof; Jack H Simon; Franz Fazekas; Marco Rovaris; Ludwig Kappos; Nicola de Stefano; Chris H Polman; John Petkau; Ernst W Radue; Maria P Sormani; David K Li; Paul O'Connor; Xavier Montalban; David H Miller; Massimo Filippi
Journal:  Nat Rev Neurol       Date:  2011-12-06       Impact factor: 42.937

3.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.

Authors:  D T Okuda; E M Mowry; B A C Cree; E C Crabtree; D S Goodin; E Waubant; D Pelletier
Journal:  Neurology       Date:  2011-01-26       Impact factor: 9.910

4.  Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.

Authors:  D T Okuda; E M Mowry; A Beheshtian; E Waubant; S E Baranzini; D S Goodin; S L Hauser; D Pelletier
Journal:  Neurology       Date:  2008-12-10       Impact factor: 9.910

5.  Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis.

Authors:  Hayrettin Tumani; Florian Deisenhammer; Gavin Giovannoni; Ralf Gold; Hans-Peter Hartung; Bernhard Hemmer; Reinhard Hohlfeld; Markus Otto; Martin Stangel; Brigitte Wildemann; Uwe K Zettl
Journal:  Ann Neurol       Date:  2011-06-27       Impact factor: 10.422

Review 6.  Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

Authors:  Ralf Gold
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

7.  Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.

Authors:  Mark S Freedman; Edward J Thompson; Florian Deisenhammer; Gavin Giovannoni; Guy Grimsley; Geoffrey Keir; Sten Ohman; Michael K Racke; Mohammad Sharief; Christian J M Sindic; Finn Sellebjerg; Wallace W Tourtellotte
Journal:  Arch Neurol       Date:  2005-06

Review 8.  Fingolimod is a potential novel therapy for multiple sclerosis.

Authors:  Orhan Aktas; Patrick Küry; Bernd Kieseier; Hans-Peter Hartung
Journal:  Nat Rev Neurol       Date:  2010-06-15       Impact factor: 42.937

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  8 in total

1.  Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

2.  Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study.

Authors:  Omar Khan
Journal:  Neurol Clin Pract       Date:  2012-12

3.  Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study.

Authors:  William J Weiner
Journal:  Neurol Clin Pract       Date:  2012-12

Review 4.  Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practices.

Authors:  Carlo Tornatore; J Theodore Phillips; Omar Khan; Aaron E Miller; Mark Hughes
Journal:  Neurol Clin Pract       Date:  2016-08

Review 5.  Nonconventional MRI biomarkers for in vivo monitoring of pathogenesis in multiple sclerosis.

Authors:  Ana C Londoño; Carlos A Mora
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-11-20

Review 6.  Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices.

Authors:  I-Jun Chou; Huei-Shyong Wang; William P Whitehouse; Cris S Constantinescu
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

7.  Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).

Authors:  Robert Zivadinov; Diane L Cookfair; Lauren Krupp; Aaron E Miller; Neil Lava; Patricia K Coyle; Andrew D Goodman; Burk Jubelt; Michael Lenihan; Joseph Herbert; Malcolm Gottesman; David H Snyder; Brian R Apatoff; Barbara E Teter; Allan B Perel; Frederick Munschauer; Bianca Weinstock-Guttman
Journal:  BMC Neurol       Date:  2016-07-15       Impact factor: 2.474

8.  Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany.

Authors:  Sabrina Müller; Tobias Heidler; Andreas Fuchs; Andreas Pfaff; Kathrin Ernst; Gunter Ladinek; Thomas Wilke
Journal:  Neurol Ther       Date:  2019-12-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.